AGMB-129
AGMB129-01-CL-109
Phase 2 small_molecule active
Quick answer
AGMB-129 for Fibrostenotic Crohn's Disease is a Phase 2 program (small_molecule) at Agomab Therapeutics NV with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Agomab Therapeutics NV
- Indication
- Fibrostenotic Crohn's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active